AL
Therapeutic Areas
Synairgen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SNG001 | Severe Viral Lung Infections in Mechanically Ventilated Patients | Phase 2 |
Leadership Team at Synairgen
MP
Mark Parry-Billings
Executive Chairman
JC
Joseph Colliver
Chief Executive Officer
DM
Dr. Marcin Mankowski
Chief Medical Officer and Head of Scientific Affairs
JB
Jody Brookes
SVP, Head of Clinical Operations
DG
Dr. Gareth Walters
Chief Regulatory Officer
RF
Richard Francis
CMC and Quality Consultant
MM
Martin Murphy
Non-Executive Director
JB
John Bradshaw
Non-Executive Director
PS
Professor Sir Stephen Holgate
Co-founder, Non-Executive Director
PR
Professor Ratko Djukanovic
Co-founder